📰 Given Innate Pharma News
Given Innate Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Given Innate Pharma. Real-time updates on events, politics, business and more.
May 30, 2024
Innate Pharma (NASDAQ:IPHA – Get Free Report) and Vitro Diagnostics (OTCMKTS:VODG – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk. Institutional & Insider Ownership 0.2% of Innate Pharma […]
May 23, 2024
Vitro Diagnostics (OTCMKTS:VODG – Get Free Report) and Innate Pharma (NASDAQ:IPHA – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability. Profitability This table compares Vitro Diagnostics and Innate […]
December 2, 2023
Editas Medicine (NASDAQ:EDIT – Get Free Report) and Innate Pharma (NASDAQ:IPHA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Institutional & Insider Ownership 76.6% of Editas […]
December 2, 2023
Innate Pharma (NASDAQ:IPHA – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Institutional & Insider Ownership 0.3% of Innate […]
January 11, 2023
Innate Pharma (NASDAQ:IPHA – Get Rating) and Voyager Therapeutics (NASDAQ:VYGR – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of recent ratings […]